Research progress on clinical characteristics and targeted therapy of airway inflammation phenotype in bronchial asthma

doi:10.19983/j.issn.2096-8493.20230123

Abstract

Abstract:

Asthma is a chronic inflammatory disease of the airway, characterized by recurrent chest tightness, cough, wheezing and shortness of breath, airflow obstruction and airway hyperresponsiveness. There is great heterogeneity in the symptoms, inflammatory patterns, and response to treatment in asthma patients, the different asthma phenotypes were identified according to the heterogeneity. Further study on the phenotype is helpful to the accurate diagnosis and treatment of asthma, so as to improve the herapeutic effect, reduce the acute attack and improve the prognosis. Using induced sputum analysis techniques to detect airway inflammation, four different inflammatory phenotypes could be identified. This article reviews the clinical characteristics, lung function characteristics and treatment progress in asthma patients with different airway inflammation phenotypes.

Key words: Asthma, Inflammation, Disease attributes

CLC Number:

R256.12

Nierjiamali·Mutalifu, Maliya·Yasheng, Kelibiena·Tuerxun. Research progress on clinical characteristics and targeted therapy of airway inflammation phenotype in bronchial asthma[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(6): 506-510. doi: 10.19983/j.issn.2096-8493.20230123

References 36

[1]	Global Initiative for Asthma. The global strategy for asthma management and prevention. California: Global Initiative for Asthma, 2015.
[2]	Brooks CR, Van Dalen CJ, Harding E, et al. Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function. BMC Pulm Med, 2017, 17(1):169. doi:10.1186/s12890-017-0511-6. pmid: 29202821
[3]	王颖, 云春梅, 刘柯含, 等. 支气管哮喘不同炎症表型的临床特征分析. 中华全科医学, 2022, 20(12):2055-2058, 2091. doi:10.16766/j.cnki.issn.1674-4152.002768.
[4]	Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet, 2006, 368(9537):804-813. doi:10.1016/S0140-6736(06)69290-8. pmid: 16935691
[5]	Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol, 2011, 127(2):355-360. doi:10.1016/j.jaci.2010.11.037. pmid: 21281866
[6]	Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. California: Global Initiative for Asthma, 2023.
[7]	Raherison-Semjen C, Parrat E, Nocent-Eijnani C, et al. FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis. Respir Res, 2021, 22 (1):136. doi:10.1186/s12931-021-01723-x.
[8]	Ricciardolo FLM, Sprio AE, Baroso A, et al. Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life. Biomedicines, 2021, 9(11):1684. doi:10.3390/biomedicines9111684.
[9]	Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, 2002, 360(9347):1715-1721. doi:10.1016/S0140-6736(02)11679-5. pmid: 12480423
[10]	Feng Y, Liu X, Wang Y, et al. Delineating asthma according to inflammation phenotypes with a focus on paucigranulocytic asthma. Chin Med J (Engl), 2023, 136(13):1513-1522. doi:10.1097/CM9.0000000000002456.
[11]	Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology, 2006, 11(1):54-61. doi:10.1111/j.1440-1843.2006.00784.x. pmid: 16423202
[12]	Simpson JL, McElduff P, Gibson PG. Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration, 2010, 79(2):147-151. doi:10.1159/000245899. pmid: 19816004
[13]	Wang F, He XY, Baines KJ, et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J, 2011, 38(3):567-574. doi:10.1183/09031936.00170110. pmid: 21233265
[14]	Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med, 2008, 178(3):218-224. doi:10.1164/rccm.200711-1754OC.
[15]	Flinkman E, Vähätalo I, Tuomisto LE, et al. Association Between Blood Eosinophils and Neutrophils With Clinical Features in Adult-Onset Asthma. J Allergy Clin Immunol Pract, 2023, 11(3):811-821.e5. doi:10.1016/j.jaip.2022.11.025.
[16]	Ntontsi P, Loukides S, Bakakos P, et al. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes. Allergy, 2017, 72(11):1761-1767. doi:10.1111/all.13184. pmid: 28407269
[17]	Papaioannou AI, Fouka E, Ntontsi P, et al. Paucigranulocytic Asthma: Potential Pathogenetic Mechanisms, Clinical Features and Therapeutic Management. J Pers Med, 2022, 12(5):850. doi:10.3390/jpm12050850.
[18]	Abdo M, Pedersen F, Kirsten AM, et al. Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma. J Allergy Clin Immunol Pract, 2022, 10(6):1545-1553.e2. doi:10.1016/j.jaip.2022.02.020. pmid: 35257957
[19]	Nadif R, Siroux V, Boudier A, et al. Blood granulocyte patterns as predictors of asthma phenotypes in adults from the EGEA study. Eur Respir J, 2016, 48(4):1040-1051. doi:10.1183/13993003.00336-2016. pmid: 27492832
[20]	Pignatti P, Visca D, Zappa M, et al. Analysis of Patients with Asthma and Mixed Granulocytic Inflammatory Pattern in Sputum. Respiration, 2022, 101(12):1121-1130. doi:10.1159/000527125. pmid: 36327948
[21]	刘志群, 于贺, 王国茗. 探讨哮喘患者的气道炎症表型分布及临床特征. 中国医药指南, 2019, 17(27):135-136. doi:10.15912/j.cnki.gocm.2019.27.114.
[22]	王子江. 532例哮喘患者的气道炎症表型及临床特征分析. 山东医药, 2016, 56(9):46-48. doi:10.3969/j.issn.1002-266X.2016.09.017.
[23]	姚润伟. 哮喘患者气道炎症表型分布及肺功能分析. 广州医药, 2019, 50(1):61-63, 112. doi:10.3969/j.issn.1000-8535.2019.01.015.
[24]	Jung JW, Kim SH, Kwon JW, et al. Clinical characteristics and long-term outcomes related to sputum eosinophilia in Korean asthmatics. Asia Pac Allergy, 2011, 1(1):16-24. doi:10.5415/apallergy.2011.1.1.16.
[25]	乐迎, 史菲. 不同哮喘表型的靶向治疗研究进展. 生物学杂志, 2018, 35(2):81-83, 87. doi:10.3969/j.issn.2095-1736.2018.02.081.
[26]	陈翠仪, 程远雄, 陈美华. 哮喘气道炎症表型与病情严重程度与治疗效果的相关性研究. 中国药业, 2015, 24(3):54-55.
[27]	Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep, 2015, 5:8191. doi:10.1038/srep08191. pmid: 25645133
[28]	Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med, 2017, 377(10):965-976. doi:10.1056/NEJMra1608969.
[29]	Li J, Kang J, Wang C, et al. Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase Ⅲ Study. Allergy Asthma Immunol Res, 2016, 8(4):319-328. doi:10.4168/aair.2016.8.4.319.
[30]	Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol, 2019, 143(5):1742-1751.e7. doi:10.1016/j.jaci.2018.09.033. pmid: 30359681
[31]	Chung KF. 2-year safety and efficacy results for benralizumab. Lancet Respir Med, 2019, 7(1):5-6. doi:10.1016/S2213-2600(18)30468-5. pmid: 30416084
[32]	Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med, 2018, 378(26):2486-2496. doi:10.1056/NEJMoa1804092.
[33]	Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol, 2008, 121(1):5-10. doi:10.1016/j.jaci.2007.10.028. pmid: 18036647
[34]	Taillé C, Poulet C, Marchand-Adam S, et al. Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series. Open Respir Med J, 2013, 7:21-25. doi:10.2174/1874306401307010021. pmid: 23526476
[35]	Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax, 2005, 60(12):1012-1018. doi:10.1136/thx.2005.045260. pmid: 16166100
[36]	Elsakkar MG, Sharaki OA, Abdallah DM, et al. Adalimumab ameliorates OVA-induced airway inflammation in mice: Role of CD4⁺ CD25⁺ FOXP3⁺ regulatory T-cells. Eur J Pharmacol, 2016, 786:100-108. doi:10.1016/j.ejphar.2016.06.002. pmid: 27262379